Prior to any study specific activities, the patient must be aware of the nature of his/her disease and willingly consent to the study after being informed of study procedures, the experimental therapy, possible alternatives, risks and potential benefitsXx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must have signed an authorization for the release of their protected health informationXx_NEWLINE_xXPatients must sign an informed consent prior to registration and before undergoing any study-specific procedures indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXParticipant must be aware of the nature of her malignancy, understand the study requirements and risks and be able and willing to sign a written informed consent documentXx_NEWLINE_xXAble to understand the investigational nature of this study and to provide written consent to participate in itXx_NEWLINE_xXCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent; in patients who are not able to consent to the trial due to medical circumstances, the next of kin or power of attorney may consent for the studyXx_NEWLINE_xXCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consentXx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients will be given a copy of the consent formXx_NEWLINE_xXAbility to understand the nature of this study and give written informed consent.Xx_NEWLINE_xXPatient must sign an informed consent document indicating that they are aware of the investigational nature of this study, which includes an authorization for the release of their protected health informationXx_NEWLINE_xXThe patient has given written informed consent after the nature of the study and alternative treatment options have been explainedXx_NEWLINE_xXInformed consent: All patients or their legal guardians (if the patient is <18 years of age) must sign an Ethics or institutional Review Board approved consent form indicating their awareness of the investigational nature and the risks of this study. When appropriate, younger patients will be included in all discussions in order to obtain assent.Xx_NEWLINE_xXPatients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks; patients unwilling or unable due to cognitive impairment to sign informed consent are excluded from the studyXx_NEWLINE_xXPatients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent formXx_NEWLINE_xXEvidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.Xx_NEWLINE_xXCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consentXx_NEWLINE_xXAbility to understand the nature of this trial and give written informed consent.Xx_NEWLINE_xXPatients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatmentXx_NEWLINE_xXPatients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study; all patients and/or their parents or legal guardians must sign a written informed consentXx_NEWLINE_xXPatients must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntary; patients must be made aware of their other treatment optionsXx_NEWLINE_xXPatients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution. Patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy.Xx_NEWLINE_xXPatients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution. Patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapyXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXAbility to comprehend the nature of the treatmentXx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXA signed informed consent form approved by the Duke University Institutional Review Board (IRB) will be required for patient enrollment into the study; patients (if 18 years old) or their parent(s) or guardian(s) must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study; all children will have to provide assent to the studyXx_NEWLINE_xXAll patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of MD Anderson Cancer Center; the only acceptable consent is the one approved by MD Anderson Institutional Review Board (IRB)Xx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must have signed an authorization for the release of their protected health information. Patients must be registered prior to treatment on study.Xx_NEWLINE_xXAll patients must be capable to voluntarily sign an informed consent indicating that they are aware of the investigational nature of this study prior to registrationXx_NEWLINE_xXPatients with a history of major psychiatric illness must be judged (by the treating physician) able to fully understand the investigational nature of the study and the risks associated with the therapyXx_NEWLINE_xXPatients must understand and sign informed consent that explains the neoplastic nature of their disease, the procedures to be followed, the experimental nature of the treatment, alternative treatments, potential risks and toxicities, and the voluntary nature of participationXx_NEWLINE_xXPatient must be aware of the neoplastic nature of his/her disease and willingly sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the studyXx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXStudy-specific informed consent approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan indicating that they are aware of the investigational nature of the treatment and the potential risks must be signed by the patientXx_NEWLINE_xXLegal guardians must sign an informed consent indicating that they are aware of this study, the possible benefits, and toxic side effects; legal guardians will be given a signed copy of the consent formXx_NEWLINE_xXPatient must willingly provide written consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.Xx_NEWLINE_xXAll patients must sign informed consent forms verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of MD Anderson Cancer Center; the only acceptable consent form is one approved by the MD Anderson institutional review boardXx_NEWLINE_xXPatients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospitalXx_NEWLINE_xXCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consentXx_NEWLINE_xXPatients must sign an informed consent form indicating that they are aware of the investigational nature of this study, in keeping with the policies of the hospitalXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXSubjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects)Xx_NEWLINE_xXPatients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXPatients must sign an informed consent and authorization indicating that they are aware of the investigational nature of this study and the known risks involvedXx_NEWLINE_xXMust be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomfortsXx_NEWLINE_xXHave signed an informed consent indicating that the patient is aware of the neoplastic nature of their disease and have been informed of the procedures of the protocol, the experimental nature of the therapy, possible alternative therapies, potential benefits, side effects, risks, and discomfortsXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXPatients must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntaryXx_NEWLINE_xXA written informed consent MUST be obtained from the patients and/or their parents/legal guardians prior to enrollment indicating their awareness of investigational nature of this studyXx_NEWLINE_xXSubject must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects).Xx_NEWLINE_xXPatients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapyXx_NEWLINE_xXPatients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefitsXx_NEWLINE_xXBe aware of the nature of her malignancyXx_NEWLINE_xXPatients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefitsXx_NEWLINE_xXCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consentXx_NEWLINE_xXWilling to sign an informed consent form, indicating awareness of the investigational nature of this study that is in keeping with the policies of the institution.Xx_NEWLINE_xXMust be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomfortsXx_NEWLINE_xXPatients must be aware of the investigational nature of the therapy and provide written informed consentXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXRECIPIENT: Ability of subject or legally authorized representative (LAR) (if the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study or written informed consent obtained from parent or legal guardian if subject is a minorXx_NEWLINE_xXPatients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent formXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXPatients must be able to understand and sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the institutional policies.Xx_NEWLINE_xXPatients must be aware of the investigational nature of the therapy and provide written informed consentXx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of MD Anderson Cancer Center (MDACC)Xx_NEWLINE_xXAll patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of M.D. Anderson Cancer Center; the only acceptable consent form is the one attached at the end of this protocol, and it must have been approved and amended by the M.D. Anderson Institutional Review Board (IRB)Xx_NEWLINE_xXAll patients must sign an informed consent approved by the Institutional Review Board indicating that they are aware of the investigational nature of this study; patients must sign an authorization for the release of their protected health informationXx_NEWLINE_xXPatients must voluntarily sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospitalXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must have signed an authorization for the release of their protected health information at all sites except the National Institutes of Health (NIH)Xx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXPatients must sign the current institutional review board (IRB) approved informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the institution, and willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study proceduresXx_NEWLINE_xXAbility to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of the studyXx_NEWLINE_xXAbility to understand and the willingness to sign a written informed consent document; the patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXPatients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent formXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: signed informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXPatients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital.Xx_NEWLINE_xXPatients must be capable of understanding of the nature of their disease and willingly give consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomfortsXx_NEWLINE_xXPatients, or legal guardians, and donors must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effectsXx_NEWLINE_xXEach patient must be aware of the nature of their disease and must willingly consent to treatment after being informed of alternatives, potential benefits, side effects, and risksXx_NEWLINE_xXPatients must sign an informed consent document that indicates they are aware of the investigative nature of the treatment in this protocol as well as the potential risks and benefitsXx_NEWLINE_xXSigned written informed consent; patient must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consentXx_NEWLINE_xXInability to understand the investigational nature of the study to provide informed consentXx_NEWLINE_xXAll patients or their legal guardians (if the patient is < 18 years old) or durable power of attorney (DPA) must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study; when appropriate, pediatric patients will be included in all discussions in order to obtain verbal assentXx_NEWLINE_xXPatients must be able to read and understand the informed consent document; patients must sign the informed consent indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXPatients must be informed of the investigative nature of the treatment, must give appropriate informed consent to protocol procedures and must sign an Informed Consent documentation formXx_NEWLINE_xXPatients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent formXx_NEWLINE_xXSigned informed consent indicating that patients are aware of the investigational nature of this study in keeping with the policies of University of Texas M.D. Anderson Cancer Center (UTMDACC)Xx_NEWLINE_xXPatients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent formXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXSigned informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written informationXx_NEWLINE_xXPatients must sign an informed consent and authorization indicating that they are aware of the investigational nature of this study and the known risks involvedXx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXPatients must understand and sign informed consent that explains the neoplastic nature of their disease, the procedures to be followed, the experimental nature of the treatment, alternative treatments, potential risks and toxicities, and the voluntary nature of participationXx_NEWLINE_xXInformed consent must be signed prior to the treatment; patients must willingly consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side effects, risks and\r\ndiscomforts; (human protection committee approval of this protocol and a consent form is required)Xx_NEWLINE_xXAbility to understand the nature of this study and give written informed consent.Xx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXPatients must sign an informed consent prior to registration and before undergoing any study-specific procedures indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXAll patients must be able to provide informed consent indicating that they are aware of the investigational nature of the study; patients must provide an authorization for the release of their protected health informationXx_NEWLINE_xXPatient is aware of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent formXx_NEWLINE_xXAll patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of MD Anderson Cancer Center; the only acceptable consent form is the one approved by MD Anderson institutional review board (IRB)Xx_NEWLINE_xXPatient (or parents/guardians, in the case of minors) must sign an informed consent document indicating that they are aware of the investigational nature of this study, which includes an authorization for the release of their protected health informationXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this programXx_NEWLINE_xXAll patients must sign a consent form indicating that they are aware of the investigational nature of the study; the informed consent form will indicate that the patient has been made aware of all other appropriate therapiesXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study.Xx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must be registered prior to treatment with study drugXx_NEWLINE_xXThe patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXSigned informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written informationXx_NEWLINE_xXSign the current Institutional Review Board (IRB) approved informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the institutionXx_NEWLINE_xXPatients must sign an informed consent and authorization indicating that they are aware of the investigational nature of this study and the known risks involvedXx_NEWLINE_xXAll patients must sign and informed consent approved by the Institutional Review Board indicating that they are aware of the investigational nature of this study; patients must also sign an authorization for the release of their protected heath informationXx_NEWLINE_xXPatients must sign an informed consent form indicating that they are aware of the investigational nature of this study, in keeping with the policies of the hospitalXx_NEWLINE_xXAbility to understand the investigational nature of this study and to give informed consentXx_NEWLINE_xXPatients must sign informed consent indicating that they are aware of the investigational nature of this study according to the policies of the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB)Xx_NEWLINE_xXAll patients must sign an IRB approved informed consent indicating their awareness of the investigational nature of this study. Patients must have signed an authorization for the release of their protected health information.Xx_NEWLINE_xXAll patients or their legal guardians (if the patients is < 18 years old) must sign an institutional review board (IRB) approved document of informed consent indicating their understanding of the investigational nature and the risks of this study BEFORE any protocol related studies are performed (this does not include routine laboratory tests or imaging studies required to establish eligibility); when appropriate, pediatric patients will be included in all discussion in order to obtain verbal assentXx_NEWLINE_xXPatients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospitalXx_NEWLINE_xXPatients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent.Xx_NEWLINE_xXEach patient must be aware of the nature of her disease process and must willingly consent to treatment after being informed of alternatives, potential benefits, side effects, and risks; eligibility testing that is considered standard of care may be done prior to informed consent but no immunotherapy related procedures or testing may occur without informed consentXx_NEWLINE_xXSigned informed consent indicating that patients are aware of the investigational nature of this study, in keeping with the policies of MD Anderson Cancer Center (MDACC), must be obtained prior to any study specific proceduresXx_NEWLINE_xXPatients must sign an informed consent form approved for this purpose by the IRB of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risksXx_NEWLINE_xXAbility to understand the nature of this study and give written informed consent.Xx_NEWLINE_xXAbility to understand the nature of this trial and give written informed consentXx_NEWLINE_xXSigned informed consent, which indicates the investigational nature of this study, is requiredXx_NEWLINE_xXSCREENING: Patients must be aware of the neoplastic nature of their illnesses, the experimental nature of the therapy, alternative treatments, potential benefits, and risksXx_NEWLINE_xXThe subject must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital.Xx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware of the investigational nature of the studyXx_NEWLINE_xXPatients must understand the nature of the study and be willing to sign an informed consent that complies with the investigator/DEKK-TEC policies and approved by the Human Investigation Review Committee. Patients must have CNS involvement - from a malignancy. Lung cancer may be either small cell or non-small cell.Xx_NEWLINE_xXPatients must sign an Informed Consent and Authorization indicating that they are aware of the investigational nature of this study and the known risks involvedXx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware of the investigational nature of this study.Xx_NEWLINE_xXBecause significant time will have elapsed between apheresis/tumor biopsy and the initiation of immunotherapy, all patients or their legal guardians (if the patient is < 18 years old) must sign a second informed consent to document their understanding of the investigational nature and the risks of this study before any protocol related studies are performed (other than the studies which were performed to determine patient eligibility)Xx_NEWLINE_xXParticipant or legal guardian, in the opinion of the investigator, is capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent; a signed informed consent must be obtained prior to any study specific proceduresXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must sign an authorization for the release of their protected health informationXx_NEWLINE_xXAll patients must sign an informed consent document indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXPatients must be aware of the neoplastic nature of their illnesses, the experimental nature of the therapy, alternative treatments, potential benefits, and risksXx_NEWLINE_xXAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must sign an authorization for the release of their protected health informationXx_NEWLINE_xXSign an informed consent indicating they are aware of the investigational nature of this studyXx_NEWLINE_xXAll patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of M.D. Anderson Cancer Center; the only acceptable consent is the one approved by M.D. Anderson Institutional Review Board (IRB)Xx_NEWLINE_xXPatients unable to give informed consent indicating they are aware of the investigational nature of this intervention prior to entry into the studyXx_NEWLINE_xXEach subject must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfortsXx_NEWLINE_xXNormal cognitive status as determined by the interviewer based on the ability to understand the nature of the study and consent process.Xx_NEWLINE_xXSCREENING PHASE: The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent formXx_NEWLINE_xXINTERVENTION PHASE: The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent formXx_NEWLINE_xXThe patient must be aware of the high risk and experimental nature of the treatment and provide informed consentXx_NEWLINE_xXThe patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent documentXx_NEWLINE_xXInformed Consent: Each patient must be aware of the neoplastic nature of his/her disease process and must willingly sign a study-specific consent prior to randomization after being informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts (human protection committee approval of this protocol and consent form is required)Xx_NEWLINE_xXAdequately informed of the nature and risks of the study with written informed consentXx_NEWLINE_xXAbility to sign informed consent and understand the nature of a placebo-controlled trialXx_NEWLINE_xXPatients must sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Hospital indicating that they are aware of the investigational nature of this MRI, of the potential but minimal risks of these additional scans, and that their treatments may or may not be altered by the results of these scansXx_NEWLINE_xXAble to comprehend the full nature and purpose of the study, including possible risks and side effects.Xx_NEWLINE_xXDONOR: Ability to comprehend the investigational nature of the study and provide informed consentXx_NEWLINE_xXIndividuals who have the ability to understand and willingness to sign an informed consent before initiation of study procedures, after the nature of the study is explained to them and they have asked any questionsXx_NEWLINE_xXSigned written informed consent (patient must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent)Xx_NEWLINE_xXPatient has been informed of the investigational nature of this study and has given written Informed Consent and is able to adhere to dosing and visit schedules and meet all study requirementsXx_NEWLINE_xXPatient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human ServicesXx_NEWLINE_xXWritten signed informed consent; patients must be aware of their diagnosis and willingly consent after being informed of the investigational nature of the intervention, alternatives, potential benefits, side-effects, risks, and discomfortsXx_NEWLINE_xXAbility to provide informed consent; all subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performedXx_NEWLINE_xXBe capable of understanding the investigational nature of the study and all pertinent aspects of the studyXx_NEWLINE_xXHEALTHY VOLUNTEER: Be able to comprehend the full nature, purpose and risks of the studyXx_NEWLINE_xXSigned informed consent indicating awareness of the investigational nature of this studyXx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the cancer centerXx_NEWLINE_xXAll patients or their legal guardians (if the patient is < 18 years of age) must sign a document of informed consent indicating their awareness of the investigational nature and the risks of this study; when appropriate, the minor patient will be asked for oral assent; the parent or guardian will sign the consent form on the designated line attesting to the fact that the minor has given assentXx_NEWLINE_xXPatients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of University of Michigan (UM) hospitalXx_NEWLINE_xXAbility to provide informed consent; all subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performedXx_NEWLINE_xXBe informed of the investigational nature of this studyXx_NEWLINE_xXNORMAL VOLUNTEERS: Be informed of the investigational nature of this studyXx_NEWLINE_xXAbility of subject or legally authorized representative (LAR) (if the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this studyXx_NEWLINE_xXThe patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent formXx_NEWLINE_xXAbility of subject to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study, and that this is not a therapeutic clinical trialXx_NEWLINE_xXAble to understand the experimental nature of the study and provide informed consentXx_NEWLINE_xXAbility to understand the investigational nature of the study and provide informed consentXx_NEWLINE_xXAltered cognitive status as determined by the interviewer based on the ability to understand the nature of the study and consent processXx_NEWLINE_xXAbility to understand the nature of this trial and give written informed consent.Xx_NEWLINE_xX